The company sees 2011 EPS of $1.10 to $1.15, up from a previous range of $1.05 to $1.12 per share, vs. consensus estimates of $1.14 per share, on revenues of $745 to $755 million, up from a previous range of $720 to $740 million,
Alexion Pharmaceuticals (NASDAQ:ALXN) reported Q2 EPS of $0.29, ahead of consensus estimates of $0.26 per share. Revenues rose 47.6% year-over-year to $185.7 million, topping consensus estimates of $178.0 million.
Alexion Pharmaceuticals has overhead space with shares priced $94.28, or 1.2% below the average consensus analyst price target of $95.44. Alexion Pharmaceuticals shares have support at the 50-day moving average (MA) of $83.45 and
A week ago, Citigroup downgraded Alexion Pharmaceuticals (ALXN) from Buy to Hold. Alexion Pharmaceuticals stocks closed at $93.37, a 3.8% gain over the course of one week.
Health care shares are higher in mid-session trading as acquisition talks between Genzyme (GENZ) and Sanofi-Aventis (SNY) take a step forward. discussions with Sanofi are said to have progressed to the point where Genzyme's board
From FNNO.com, this is the Financial News Network. I’m Cleo
Stiller-Farrell and this is your Midweek Market Wrap Up. The British
Bankers’ Association, which has the supervisory role of setting the
influential Libor rates, announced that it would be willing to give up
its...
The Wall Street Journal reports that home prices showed their best year-to-date gains since 2005, up 5.9% through July, signaling the housing market's steady march toward recovery. Also from the Wall Street Journal, IBM (IBM) will increase its efforts to sell so-called cloud computing services...
CEO Marissa Mayer is bringing in some more new blood to Yahoo!, tapping Ken Goldman as the company's new Chief Financial Officer. Goldman's appointment will take effect on October 22nd.
Goldman served as CFO at his most recent employer, Fortinet, having worked at Siebel Systems, Sybase,...